Abel Hall LLC Has $444,000 Position in Bristol Myers Squibb Company $BMY

Abel Hall LLC reduced its position in shares of Bristol Myers Squibb Company (NYSE:BMY) by 41.2% in the 2nd quarter, Holdings Channel reports. The institutional investor owned 9,596 shares of the biopharmaceutical company’s stock after selling 6,727 shares during the quarter. Abel Hall LLC’s holdings in Bristol Myers Squibb were worth $444,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently modified their holdings of the company. Proffitt & Goodson Inc. acquired a new position in shares of Bristol Myers Squibb during the second quarter worth about $67,000. REAP Financial Group LLC raised its holdings in Bristol Myers Squibb by 202.8% during the second quarter. REAP Financial Group LLC now owns 639 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 428 shares in the last quarter. BankPlus Trust Department raised its holdings in Bristol Myers Squibb by 11.7% during the second quarter. BankPlus Trust Department now owns 34,261 shares of the biopharmaceutical company’s stock worth $1,586,000 after acquiring an additional 3,585 shares in the last quarter. Shell Asset Management Co. raised its holdings in Bristol Myers Squibb by 38.0% during the second quarter. Shell Asset Management Co. now owns 86,338 shares of the biopharmaceutical company’s stock worth $3,997,000 after acquiring an additional 23,772 shares in the last quarter. Finally, Joel Isaacson & Co. LLC raised its holdings in Bristol Myers Squibb by 10.3% during the second quarter. Joel Isaacson & Co. LLC now owns 25,598 shares of the biopharmaceutical company’s stock worth $1,185,000 after acquiring an additional 2,386 shares in the last quarter. 76.41% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Bristol Myers Squibb

In other news, EVP David V. Elkins sold 56,000 shares of the stock in a transaction that occurred on Tuesday, September 2nd. The stock was sold at an average price of $47.33, for a total transaction of $2,650,480.00. Following the transaction, the executive vice president owned 167,379 shares in the company, valued at approximately $7,922,048.07. This trade represents a 25.07% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.07% of the company’s stock.

Bristol Myers Squibb Stock Performance

BMY opened at $44.63 on Wednesday. Bristol Myers Squibb Company has a 12-month low of $42.96 and a 12-month high of $63.33. The stock has a market cap of $90.84 billion, a price-to-earnings ratio of 18.00, a PEG ratio of 2.31 and a beta of 0.33. The business has a 50 day moving average of $46.27 and a 200-day moving average of $48.36. The company has a quick ratio of 1.11, a current ratio of 1.21 and a debt-to-equity ratio of 2.54.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported $1.46 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.07 by $0.39. The company had revenue of $12.27 billion during the quarter, compared to analysts’ expectations of $11.32 billion. Bristol Myers Squibb had a return on equity of 80.04% and a net margin of 10.58%.The business’s revenue was up .6% on a year-over-year basis. During the same period last year, the firm posted $2.07 earnings per share. Bristol Myers Squibb has set its FY 2025 guidance at 6.350-6.650 EPS. On average, equities research analysts expect that Bristol Myers Squibb Company will post 6.74 earnings per share for the current year.

Bristol Myers Squibb Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, November 3rd. Stockholders of record on Friday, October 3rd will be paid a dividend of $0.62 per share. The ex-dividend date is Friday, October 3rd. This represents a $2.48 dividend on an annualized basis and a dividend yield of 5.6%. Bristol Myers Squibb’s dividend payout ratio (DPR) is 100.00%.

Analysts Set New Price Targets

BMY has been the topic of several analyst reports. Morgan Stanley reiterated a “hold” rating on shares of Bristol Myers Squibb in a report on Thursday, July 31st. Daiwa America lowered Bristol Myers Squibb from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 5th. Dbs Bank upgraded Bristol Myers Squibb to a “moderate buy” rating in a report on Thursday, October 2nd. Citigroup dropped their target price on Bristol Myers Squibb from $51.00 to $47.00 and set a “neutral” rating on the stock in a report on Friday, August 1st. Finally, Daiwa Capital Markets lowered Bristol Myers Squibb from an “outperform” rating to a “neutral” rating and set a $42.00 target price on the stock. in a report on Tuesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and fifteen have given a Hold rating to the stock. Based on data from MarketBeat.com, Bristol Myers Squibb presently has an average rating of “Hold” and a consensus target price of $57.14.

Bristol Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.